A pharmacokinetic study of oclacitinib maleate in six cats.

Abstract

Oclacitinib is a Janus kinase (JK)1 inhibitor that has been shown to be effective and safe for the treatment of allergic dermatitis in dogs. Its use in cats has been limited by the absence of pharmacokinetic data. To determine the pharmacokinetic parameters of oclacitinib in cats after oral and intravenous administration. Six adult domestic short hair cats. A two period, two treatment design was used in which cats received oclacitinib maleate i.v. and p.o., at a dose of 0.5mg/kg and 1mg/kg, respectively. There was a one-week interval of washout between the two treatments. Cats received each treatment only once. The plasma concentration of oclacitinib was determined by high-performance liquid chromatography at 0min, 5min, 15min, 30min, 1h, 4h, 6h, 10h and 24h after intravenous.v administration, at 0min, 15min, 30min, 1h, 2h, 4h, 6h, 10h and 24h after p.o. administration. After p.o. administration, oclacitinib was absorbed rapidly and almost completely, as shown by an absolute bioavailability of 87% and a Tmax of 35min. The elimination of the drug also was very rapid as shown by a half-life of 2.3h and a clearance calculated as 4.45mL/min/kg (after i.v. administration). The pharmacokinetic parameters of oclacitinib in the cat are similar to those described for the dog, although absorption and elimination are somewhat faster and variability between individuals is somewhat greater. Larger doses and/or shorter dosing intervals would be recommended in cats to achieve similar blood concentrations to those in dogs.